Compare ISD & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ISD | EOLS |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.4M | 444.0M |
| IPO Year | N/A | 2018 |
| Metric | ISD | EOLS |
|---|---|---|
| Price | $14.42 | $7.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.80 |
| AVG Volume (30 Days) | 127.1K | ★ 964.5K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 9.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $285,823,000.00 |
| Revenue This Year | N/A | $14.36 |
| Revenue Next Year | N/A | $23.27 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 15.10 |
| 52 Week Low | $10.98 | $5.71 |
| 52 Week High | $13.17 | $17.12 |
| Indicator | ISD | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 43.36 | 56.80 |
| Support Level | $14.38 | $7.05 |
| Resistance Level | $14.52 | $7.34 |
| Average True Range (ATR) | 0.10 | 0.26 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 6.06 | 87.84 |
PGIM High Yield Fund Inc is a diversified, closed-end management investment company, active in the financial services domain. The fund's primary investment objective is to provide a high level of current income, with its secondary objective being capital appreciation. It invests at least eighty percent of its investable assets in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.